{"success":true,"data":{"pressRelease":{"id":"168864","rtpr_id":"nNFC8VynKW-20261014","ticker":"BETR","exchange":"","all_tickers":["BETR"],"title":"BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair","author":"Newsfile Corp","published_at":"2026-10-14T12:00:19.430Z","article_body":"Brain Prize co-recipient whose research identified CGRP as a central driver of\nmigraine joins to guide development of BETR-001 in chronic cluster headache\nand chronic migraine\n\nVancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife\nPharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) (\"BetterLife\" or the\n\"Company\"), a biotechnology company developing BETR-001 for chronic cluster\nheadache and chronic migraine, today announced the formation of a Scientific\nAdvisory Board (\"SAB\") to guide the clinical development of BETR-001.\nProfessor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair.\n\nThe SAB will advise the Company's management and Board of Directors on\nclinical development strategy, the design and conduct of its planned clinical\nstudies in chronic cluster headache and chronic migraine, and the scientific\nbasis for its interactions with regulators.\n\nProfessor Goadsby is internationally recognized for research that has changed\nhow headache in general and migraine in particular is understood and treated.\nHis work identified calcitonin gene-related peptide (CGRP) as a central driver\nof migraine, research that led to an entirely new class of migraine-specific\nmedicines now used by millions of patients. He was a co-recipient of the 2021\nBrain Prize, the world's largest neuroscience award, and was elected a Fellow\nof the Royal Society in 2022. His clinical and research career has spanned\nboth migraine and cluster headache.\n\nProfessor Goadsby currently serves as Senior Associate to the President and\nFounding Dean of the Division of Biomedical Sciences at King Abdullah\nUniversity of Science and Technology (KAUST). He also holds appointments as\nProfessor of Neurology at King's College London, and Honorary Consultant\nNeurologist at King's College Hospital and Great Ormond Street Hospital for\nChildren, London. He is a National Institute for Health and Care Research\nEmeritus Senior Investigator and Emeritus Professor of Neurology at the\nUniversity of California, Los Angeles. He previously held faculty positions at\nUniversity College London and the National Hospital for Neurology and\nNeurosurgery, Queen Square, and at the University of California, San\nFrancisco.\n\n\"Chronic cluster headache is one of the most disabling conditions in\nneurology, and patients who do not respond to current preventive treatment\nhave very few options,\" said Professor Goadsby. \"Progress in this field has\nalways depended on asking precise clinical questions and designing studies\nthat can answer them. I look forward to working with the BetterLife team as\nBETR-001 moves toward the clinic.\"\n\n\"Peter Goadsby helped build the modern science of headache medicine,\" said\nDouglas Drysdale, Executive Chair of BetterLife's Board of Directors. \"We\nintend to use his judgment where it matters most: in how we design, run and\ninterpret our studies. His deep insight and expertise in headache will be\ninvaluable to us. Having him co-chair the SAB as we prepare our IND is a\nsignificant step for the program.\"\n\nIn connection with his appointment, the Company has agreed to grant Professor\nGoadsby stock options to purchase 500,000 common shares of BetterLife, with\nquarterly vesting over 24 months and a ten (10) year term. Exercise price for\nthe stock options will be in accordance with the policies of the Canadian\nSecurities Exchange.\n\nAbout BETR-001\n\nBETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid\ndiethylamide (2-Br-LSD) in development for the preventive treatment of chronic\ncluster headache and chronic migraine. The Company holds a granted U.S.\ncomposition-of-matter patent covering BETR-001. BETR-001 is an investigational\nproduct and has not been approved by any regulatory authority.\n\nAbout BetterLife Pharma Inc.\n\nBetterLife Pharma Inc. is an emerging biotechnology company primarily focused\non developing and commercializing BETR-001 to treat various neurological\ndisorders, such as chronic cluster headache and chronic migraine.\n\nFor further information, please visit BetterLife Pharma\n(https://api.newsfilecorp.com/redirect/oPBkLfaL2j).\n\nInstitutional affiliations are provided for identification purposes only and\ndo not imply endorsement of the Company or BETR-001 by those institutions.\n\nContact\n\nAhmad Doroudian, Chief Executive Officer\nEmail: Ahmad.Doroudian@blifepharma.com\nPhone: 1-604-221-0595\n\nCautionary Note Regarding Forward-Looking Information\n\nNo securities exchange has reviewed nor accepts responsibility for the\nadequacy or accuracy of the content of this news release. This news release\nmay contain forward-looking statements that are not historical facts.\nForward-looking statements are often identified by terms such as \"will\",\n\"may\", \"should\", \"anticipate\", \"expects\" and similar expressions.\nForward-looking statements include, but are not limited to, statements\nregarding the role and activities of the Scientific Advisory Board, the\nCompany's planned clinical studies, its planned Investigational New Drug\napplication, and the development of BETR-001. All statements other than\nstatements of historical fact, included in this release are forward-looking\nstatements that involve risks and uncertainties. There can be no assurance\nthat such statements will prove to be accurate and actual results and future\nevents could differ materially from those anticipated in such statements.\nImportant factors that could cause actual results to differ materially from\nthe Company's expectations include the failure to satisfy the conditions of\nthe relevant securities exchange(s) and other risks detailed from time to time\nin the filings made by the Company with securities regulations. The reader is\ncautioned that assumptions used in the preparation of any forward-looking\ninformation may prove to be incorrect. Events or circumstances may cause\nactual results to differ materially from those predicted, as a result of\nnumerous known and unknown risks, uncertainties, and other factors, many of\nwhich are beyond the control of the Company. The reader is cautioned not to\nplace undue reliance on any forward-looking information. Such information,\nalthough considered reasonable by management at the time of preparation, may\nprove to be incorrect and actual results may differ materially from those\nanticipated. Forward-looking statements contained in this news release are\nexpressly qualified by this cautionary statement. The forward-looking\nstatements contained in this news release are made as of the date of this news\nrelease and the Company will update or revise publicly any of the included\nforward-looking statements as expressly required by applicable law.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/318738","article_body_html":"","raw_payload":{"data":{"id":"nNFC8VynKW-20261014","title":"BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair","author":"Newsfile Corp","ticker":"BETR","created":"2026-10-14T12:00:19.430Z","tickers":["BETR"],"exchange":"","article_body":"Brain Prize co-recipient whose research identified CGRP as a central driver of\nmigraine joins to guide development of BETR-001 in chronic cluster headache\nand chronic migraine\n\nVancouver, British Columbia--(Newsfile Corp. - October 14, 2026) - BetterLife\nPharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) (\"BetterLife\" or the\n\"Company\"), a biotechnology company developing BETR-001 for chronic cluster\nheadache and chronic migraine, today announced the formation of a Scientific\nAdvisory Board (\"SAB\") to guide the clinical development of BETR-001.\nProfessor Peter Goadsby, MD, PhD, FRS, has been appointed Co-Chair.\n\nThe SAB will advise the Company's management and Board of Directors on\nclinical development strategy, the design and conduct of its planned clinical\nstudies in chronic cluster headache and chronic migraine, and the scientific\nbasis for its interactions with regulators.\n\nProfessor Goadsby is internationally recognized for research that has changed\nhow headache in general and migraine in particular is understood and treated.\nHis work identified calcitonin gene-related peptide (CGRP) as a central driver\nof migraine, research that led to an entirely new class of migraine-specific\nmedicines now used by millions of patients. He was a co-recipient of the 2021\nBrain Prize, the world's largest neuroscience award, and was elected a Fellow\nof the Royal Society in 2022. His clinical and research career has spanned\nboth migraine and cluster headache.\n\nProfessor Goadsby currently serves as Senior Associate to the President and\nFounding Dean of the Division of Biomedical Sciences at King Abdullah\nUniversity of Science and Technology (KAUST). He also holds appointments as\nProfessor of Neurology at King's College London, and Honorary Consultant\nNeurologist at King's College Hospital and Great Ormond Street Hospital for\nChildren, London. He is a National Institute for Health and Care Research\nEmeritus Senior Investigator and Emeritus Professor of Neurology at the\nUniversity of California, Los Angeles. He previously held faculty positions at\nUniversity College London and the National Hospital for Neurology and\nNeurosurgery, Queen Square, and at the University of California, San\nFrancisco.\n\n\"Chronic cluster headache is one of the most disabling conditions in\nneurology, and patients who do not respond to current preventive treatment\nhave very few options,\" said Professor Goadsby. \"Progress in this field has\nalways depended on asking precise clinical questions and designing studies\nthat can answer them. I look forward to working with the BetterLife team as\nBETR-001 moves toward the clinic.\"\n\n\"Peter Goadsby helped build the modern science of headache medicine,\" said\nDouglas Drysdale, Executive Chair of BetterLife's Board of Directors. \"We\nintend to use his judgment where it matters most: in how we design, run and\ninterpret our studies. His deep insight and expertise in headache will be\ninvaluable to us. Having him co-chair the SAB as we prepare our IND is a\nsignificant step for the program.\"\n\nIn connection with his appointment, the Company has agreed to grant Professor\nGoadsby stock options to purchase 500,000 common shares of BetterLife, with\nquarterly vesting over 24 months and a ten (10) year term. Exercise price for\nthe stock options will be in accordance with the policies of the Canadian\nSecurities Exchange.\n\nAbout BETR-001\n\nBETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid\ndiethylamide (2-Br-LSD) in development for the preventive treatment of chronic\ncluster headache and chronic migraine. The Company holds a granted U.S.\ncomposition-of-matter patent covering BETR-001. BETR-001 is an investigational\nproduct and has not been approved by any regulatory authority.\n\nAbout BetterLife Pharma Inc.\n\nBetterLife Pharma Inc. is an emerging biotechnology company primarily focused\non developing and commercializing BETR-001 to treat various neurological\ndisorders, such as chronic cluster headache and chronic migraine.\n\nFor further information, please visit BetterLife Pharma\n(https://api.newsfilecorp.com/redirect/oPBkLfaL2j).\n\nInstitutional affiliations are provided for identification purposes only and\ndo not imply endorsement of the Company or BETR-001 by those institutions.\n\nContact\n\nAhmad Doroudian, Chief Executive Officer\nEmail: Ahmad.Doroudian@blifepharma.com\nPhone: 1-604-221-0595\n\nCautionary Note Regarding Forward-Looking Information\n\nNo securities exchange has reviewed nor accepts responsibility for the\nadequacy or accuracy of the content of this news release. This news release\nmay contain forward-looking statements that are not historical facts.\nForward-looking statements are often identified by terms such as \"will\",\n\"may\", \"should\", \"anticipate\", \"expects\" and similar expressions.\nForward-looking statements include, but are not limited to, statements\nregarding the role and activities of the Scientific Advisory Board, the\nCompany's planned clinical studies, its planned Investigational New Drug\napplication, and the development of BETR-001. All statements other than\nstatements of historical fact, included in this release are forward-looking\nstatements that involve risks and uncertainties. There can be no assurance\nthat such statements will prove to be accurate and actual results and future\nevents could differ materially from those anticipated in such statements.\nImportant factors that could cause actual results to differ materially from\nthe Company's expectations include the failure to satisfy the conditions of\nthe relevant securities exchange(s) and other risks detailed from time to time\nin the filings made by the Company with securities regulations. The reader is\ncautioned that assumptions used in the preparation of any forward-looking\ninformation may prove to be incorrect. Events or circumstances may cause\nactual results to differ materially from those predicted, as a result of\nnumerous known and unknown risks, uncertainties, and other factors, many of\nwhich are beyond the control of the Company. The reader is cautioned not to\nplace undue reliance on any forward-looking information. Such information,\nalthough considered reasonable by management at the time of preparation, may\nprove to be incorrect and actual results may differ materially from those\nanticipated. Forward-looking statements contained in this news release are\nexpressly qualified by this cautionary statement. The forward-looking\nstatements contained in this news release are made as of the date of this news\nrelease and the Company will update or revise publicly any of the included\nforward-looking statements as expressly required by applicable law.\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/318738"},"type":"article","timestamp":"2026-10-14T12:00:19.496554369Z","server_sent_at_ms":1791979219496},"received_at":"2026-10-14T12:00:19.547Z","source_url":"https://www.newsfilecorp.com/release/318738"},"analysis":{"id":"157117","press_release_id":"168864","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["advisory compensation in stock options (500,000 options) adds modest dilution for a micro-cap","BETR-001 remains investigational and unapproved; still pre-IND"],"eventType":"board_change","narrative":"BetterLife Pharma formed a Scientific Advisory Board to guide development of BETR-001 in chronic cluster headache and chronic migraine, appointing Professor Peter Goadsby as Co-Chair.\n\nGoadsby is a 2021 Brain Prize co-recipient whose research identified CGRP as a central driver of migraine, and he will advise on study design and regulatory strategy ahead of a planned IND submission.\n\nIn connection with the appointment, BetterLife agreed to grant Goadsby options on 500,000 shares with quarterly vesting over 24 months and a ten-year term.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Top headache researcher Goadsby joins BetterLife SAB ahead of planned IND -- scientific validation, no near-term catalyst."},"keyFigures":{"customDimensions":{"option_term_years":10,"option_vesting_months":24,"stock_options_granted":500000}},"quotedText":"Peter Goadsby helped build the modern science of headache medicine","namedEntities":{"people":[{"name":"Peter Goadsby","role":"SAB Co-Chair; Professor of Neurology, King's College London"},{"name":"Douglas Drysdale","role":"Executive Chair, Board of Directors"},{"name":"Ahmad Doroudian","role":"Chief Executive Officer"}],"products":["BETR-001","2-bromo-lysergic acid diethylamide (2-Br-LSD)"],"companies":[{"name":"BetterLife Pharma Inc.","ticker":"BETR","relationship":"filer"},{"name":"King's College London","relationship":"Goadsby institutional affiliation"},{"name":"King Abdullah University of Science and Technology (KAUST)","relationship":"Goadsby institutional affiliation"},{"name":"University of California, Los Angeles","relationship":"Goadsby institutional affiliation"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Formation of a Scientific Advisory Board with a world-class headache researcher (Peter Goadsby) as Co-Chair is a credibility-positive but routine pre-IND governance step for a micro-cap biotech; no clinical, financial, or regulatory event occurred."},"tickerRelevance":{"others":[],"primary":"BETR"},"globalImportance":12,"audienceRelevance":8,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"micro-cap","dilutionRisk":"minor-options-grant","eventGravity":"advisory-board-formation","issuerAuthored":true}},"event_type":"board_change","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":2,"narrative":"BetterLife Pharma formed a Scientific Advisory Board to guide development of BETR-001 in chronic cluster headache and chronic migraine, appointing Professor Peter Goadsby as Co-Chair.\n\nGoadsby is a 2021 Brain Prize co-recipient whose research identified CGRP as a central driver of migraine, and he will advise on study design and regulatory strategy ahead of a planned IND submission.\n\nIn connection with the appointment, BetterLife agreed to grant Goadsby options on 500,000 shares with quarterly vesting over 24 months and a ten-year term.","key_figures":{"customDimensions":{"option_term_years":10,"option_vesting_months":24,"stock_options_granted":500000}},"named_entities":{"people":[{"name":"Peter Goadsby","role":"SAB Co-Chair; Professor of Neurology, King's College London"},{"name":"Douglas Drysdale","role":"Executive Chair, Board of Directors"},{"name":"Ahmad Doroudian","role":"Chief Executive Officer"}],"products":["BETR-001","2-bromo-lysergic acid diethylamide (2-Br-LSD)"],"companies":[{"name":"BetterLife Pharma Inc.","ticker":"BETR","relationship":"filer"},{"name":"King's College London","relationship":"Goadsby institutional affiliation"},{"name":"King Abdullah University of Science and Technology (KAUST)","relationship":"Goadsby institutional affiliation"},{"name":"University of California, Los Angeles","relationship":"Goadsby institutional affiliation"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T12:00:40.100Z","global_importance":12,"audience_relevance":8,"importance_components":{"tickerTier":"micro-cap","dilutionRisk":"minor-options-grant","eventGravity":"advisory-board-formation","issuerAuthored":true}},"durationMs":7422,"modelName":"glm-5.3-flashx"}}